Please login to the form below

Not currently logged in

BMS/Gilead HIV deal

Bristol-Myers Squibb and Gilead Sciences sign licensing agreement to develop and market a new fixed-dose combination HIV treatment

Bristol-Myers Squibb (BMS) and Gilead Sciences have signed a licensing agreement to develop and market a new fixed-dose combination HIV treatment.

The therapy contains BMS' protease inhibitor Reyataz (atazanavir sulfate) and Gilead's cobicistat, a pharmacoenhancing agent that increases blood levels of certain HIV medicines to potentially allow for one pill once daily dosing.

Gilead is currently studying atazanavir and cobicistat in phase II and III studies in HIV-1 treatment-naïve patients.

Under the terms of the agreement, BMS will pay Gilead an undisclosed royalty based on annual net sales of the product.

BMS will be responsible for the formulation, manufacturing, development, registration, distribution, and commercialisation of the fixed-dose combination worldwide.

Gilead retains sole rights for the manufacture, development and commercialization of cobicistat as a stand-alone product and for use in combination with other agents.

Dr Elliott Sigal, executive vice president, chief scientific officer and president, R&D, BMS, said: "A Reyataz and cobicistat fixed-dose combination has the potential not only to help simplify HIV therapy but also to address an unmet medical need in HIV for additional, innovative treatment options."

27th October 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Lucid Group Communications Limited

We are industry-leading thinkers when it comes to education. We use the latest academic thinking on the psychology of behaviour...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...